Kasvu Therapeutics
Lately:3 news stories in 90 daysFollow changes →
Facts
as of Nov 20, 2026Potent, rapid-acting and long-lasting without hallucinations – Kasvu develops first and best-in-class small molecule neuroplastogens for diseases where neuronal connectivity is altered.
- Employees
- 51-200estimated range
- Website
- kasvutx.com
These are the key facts about Kasvu Therapeutics on Alion as of Nov 20, 2026. The latest round is Series A of $32.4M, announced in 2026.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
Funding
Full ledger, 1 record →Kasvu Therapeutics has $32.4M paid in by investors, lenders and donors.
$32.4MPaid in
Money innewest first
$32.4MPaid
Money by yearUSD, rounds and grants
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
Ownership
All holders and entities →Sources name Hadean Ventures among the owners or investors of Kasvu Therapeutics.
Named investors, no share stated1
Holders and shares as each register or filing states them.
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Milestones
Sep 24
Raised a round Series A $32.4M · led by Hadean Ventures · YahooFinance
Each milestone is dated by its source: registers, filings, the press
Newsroom
Sep 242026
News · University of Helsinki
Kasvu Therapeutics, a University of Helsinki spinout, raised €30 million to develop a novel depression drug. The company arose from the University's breakthrough research.
Sep 242026
Press release · The Manila Times
Kasvu Therapeutics Raises €30 Million Series A Financing Round led by Hadean Ventures to Advance its Novel TrkB Potentiator into Clinical Development Targeting Neuropsychiatric D…
Sources: the outlets named on each headline, each story once
